Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Eisenhower Health Purchases Neuro Vitality Center
Rancho Mirage, California-based Eisenhower Health announced that it has purchased the Neuro Vitality Center in California. Neuro Vitality Center, formerly the Stroke Recovery Center, is a medical clinic that has served neurologically challenged and chronically ill patients in the Palm Springs, California community since 1978. In partnership with Los Angeles Jewish Health, Eisenhower will provide a Program of All-Inclusive Care for the Elderly (PACE) at the former Neuro Vitality Center location. Eisenhower Health is a not-for-profit, comprehensive healthcare institution that includes the 437-bed Eisenhower Hospital, the Barbara Sinatra Children’s Center at Eisenhower and the Annenberg... Read More »
StatLab Medical Products Acquires Poly Scientific R&D
McKinney, Texas-based StatLab Medical Products announced that it has acquired Poly Scientific R&D. Poly Scientific is one of the leading manufacturers of chemicals, stains and reagents for histology, cytology and microbiology, as well as other items for in-vitro diagnostic testing. The company was founded in 1969 and is based in Bay Shore, New York. StatLab Medical Products, an Audax Private Equity and Linden Capital Partners portfolio company, is a McKinney, Texas-based developer and manufacturer of histology, cytology and immunohistochemistry diagnostic products. The company partners with anatomic pathology laboratories to provide easy access to more than 3,500... Read More »
Juvisé Pharmaceuticals Purchases Global Rights to PONVORY
On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple sclerosis; it is protected by several patents, the latest of which expires in 2035. Founded in 2008, Juvise Pharmaceuticals is an international pharmaceutical company based in Villeurbanne, France. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry and rheumatology,... Read More »
Best Life Brands Announces Latest Acquisition of Next Day Access
Best Life Brands, a portfolio company of private equity firm The Riverside Company, announced that it has added another home-focused company to its portfolio. The company will acquire Next Day Access, according to a March 25 press release. Next Day Access is a leading provider of home access solutions to homeowners and businesses across the United States and Canada. The company offers wheelchair ramps, stair lifts, porch lifts, patient lifts, grab bar installations, auto lifts, pool lifts, mobility scooters and other mobility equipment, as well as durable medical equipment such as manual wheelchairs, super poles, shower benches, transfer benches, toilet safety frames, hospital beds... Read More »
Novo Nordisk Inks $1 Billion Buyout of Cardior Pharmaceuticals
Novo Nordisk announced that it has agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion (approximately $1.1 billion USD), including an upfront payment and additional payments if certain development and commercial milestones are achieved. The acquisition is an important step forward in Novo Nordisk’s strategy to establish a presence in the cardiovascular disease treatment space. Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse cardiovascular diseases. Cardior’s therapeutic approach uses distinctive non-coding RNAs as a platform for addressing... Read More »
Why Invest in the Health Clinic Market
We sat down and spoke with industry expert Andre Ulloa, Partner and Executive Advisor of M&A Healthcare Advisors, to discuss the key considerations investors should know before investing in the health clinic market. Ulloa sheds light on the factors driving the recent surge in health clinic investment, and what’s to come for this booming market. What is a Health Clinic? A health clinic, also called a walk-in clinic, is a convenient option for immediate, non-emergency medical care. These types of clinics can treat a wide range of conditions, such as the flu, strep throat, small cuts and skin infections. They can also provide services like physical exams, immunizations and similar... Read More »
Trinity Health Michigan Acquires West Michigan Rheumatology
Trinity Health Michigan has entered into an agreement to acquire West Michigan Rheumatology, a three-provider practice. Based in Grand Rapids, Michigan, West Michigan Rheumatology has provided care to patients suffering from a variety of rheumatological conditions throughout West Michigan for more than 25 years. The clinical team collaborates closely with other specialists such as physical therapists, occupational therapists and nutritionists to provide a holistic treatment plan for patients. Trinity Health Michigan, also called Trinity Health Medical Group, is one of the largest not-for-profit, Catholic health care systems in the nation. With more than 24,000 full-time... Read More »AbbVie Acquires Landos Biopharma for $137.5 Million
On March 25, Chicago-based AbbVie Inc. announced that it entered into an agreement to acquire Landos Biopharma for $137.5 million. AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class oral NLRX1... Read More »
